Bionomics
Bionomics Limited engages in the discovery and development of therapeutics for cancer and diseases of the central nervous system in Australia. It has small molecule product development programs in the areas of cancer, anxiety, epilepsy, and multiple sclerosis. The company develops its lead cancer compound, BNC 105, for the treatment of solid tumors, such as breast, lung, colon, and prostate cancers. BNC 105 is a member of the class of compounds, known as vascular disruption agents or VDAs, which shut down the blood supply within a tumor, starving the tumor and preventing its continued growth. The company has commercial partnerships with Genmab A/S; Athena Diagnostics; Laboratory Corporation of America; and Genetic Technologies, Ltd. Bionomics Limited was founded in 1999 and is based in Thebarton, Australia.
Prestwick Chemical is a French Contract Research Organization (CRO) established in 1999 by Professor C.G. Wermuth, a noted expert in pharmacology and medicinal chemistry. The company specializes in early drug discovery, offering smart chemical screening libraries and medicinal chemistry services aimed at accelerating the development of innovative small molecule drugs. Prestwick Chemical serves a diverse clientele, including pharmaceutical and biotechnology companies, research institutes, and academic groups, and also engages in projects related to cosmetics, veterinary medicine, and agro-pharmaceuticals. Over the past decade, the company has gained international recognition for enhancing the drug discovery process through tailor-made services and a portfolio designed to maximize chemical diversity, thereby improving the chances of success in hit finding and fragment-based drug discovery.
Eclipse Therapeutics, Inc. is a private biotechnology company focused on discovering and developing innovative therapeutics aimed at targeting cancer stem cells (CSCs) and other cancer treatment modalities. The company utilizes a unique biotechnology platform to create novel therapeutic products designed to address the complexities of cancer treatment. Through its commitment to advancing cancer therapies, Eclipse Therapeutics seeks to improve patient outcomes and contribute to the ongoing fight against cancer.
Iliad Chemicals Pty Limited develops a library of novel molecules that act as potent tubulin polymerisation inhibitors for treating cancer. The company utilizes MultiCore Chemistry technology platform to provide synthesis of molecules and develop chemical libraries.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.